» Articles » PMID: 36551859

Glial Contributions to Lafora Disease: A Systematic Review

Overview
Journal Biomedicines
Date 2022 Dec 23
PMID 36551859
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Lafora disease (LD) is a neurodegenerative condition characterized by the accumulation of polyglucosan bodies (PBs) throughout the brain. Alongside metabolic and molecular alterations, neuroinflammation has emerged as another key histopathological feature of LD.

Methods: To investigate the role of astrocytes and microglia in LD, we performed a systematic review according to the PRISMA statement. PubMed, Scopus, and Web-of-Science database searches were performed independently by two reviewers.

Results: Thirty-five studies analyzing the relationship of astrocytes and microglia with LD and/or the effects of anti-inflammatory treatments in LD animal models were identified and included in the review. Although LD has long been dominated by a neuronocentric view, a growing body of evidence suggests a role of glial cells in the disease, starting with the finding that these cells accumulate PBs. We discuss the potential meaning of glial PB accumulations, the likely factors activating glial cells, and the possible contribution of glial cells to LD neurodegeneration and epilepsy.

Conclusions: Given the evidence for the role of neuroinflammation in LD, future studies should consider glial cells as a potential therapeutic target for modifying/delaying LD progression; however, it should be kept in mind that these cells can potentially assume multiple reactive phenotypes, which could influence the therapeutic response.

Citing Articles

Glycogen synthase GYS1 overactivation contributes to glycogen insolubility and malto-oligoglucan-associated neurodegenerative disease.

Nitschke S, Montalbano A, Whiting M, Smith B, Mukherjee-Roy N, Marchioni C EMBO J. 2025; 44(5):1379-1413.

PMID: 39806098 PMC: 11876434. DOI: 10.1038/s44318-024-00339-3.


Dapagliflozin ameliorates Lafora disease phenotype in a zebrafish model.

Della Vecchia S, Imbrici P, Liantonio A, Naef V, Damiani D, Licitra R Biomed Pharmacother. 2025; 183:117800.

PMID: 39753095 PMC: 11794196. DOI: 10.1016/j.biopha.2024.117800.


Neurological glycogen storage diseases and emerging therapeutics.

Colpaert M, Singh P, Donohue K, Pires N, Fuller D, Corti M Neurotherapeutics. 2024; 21(5):e00446.

PMID: 39277505 PMC: 11581880. DOI: 10.1016/j.neurot.2024.e00446.

References
1.
Pellegrini P, Hervera A, Varea O, Brewer M, Lopez-Soldado I, Guitart A . Lack of p62 Impairs Glycogen Aggregation and Exacerbates Pathology in a Mouse Model of Myoclonic Epilepsy of Lafora. Mol Neurobiol. 2021; 59(2):1214-1229. PMC: 8857170. DOI: 10.1007/s12035-021-02682-6. View

2.
Ren M, Guo Q, Guo L, Lenz M, Qian F, Koenen R . Polymerization of MIP-1 chemokine (CCL3 and CCL4) and clearance of MIP-1 by insulin-degrading enzyme. EMBO J. 2010; 29(23):3952-66. PMC: 3020635. DOI: 10.1038/emboj.2010.256. View

3.
Knecht E, Criado-Garcia O, Aguado C, Gayarre J, Duran-Trio L, Garcia-Cabrero A . Malin knockout mice support a primary role of autophagy in the pathogenesis of Lafora disease. Autophagy. 2012; 8(4):701-3. DOI: 10.4161/auto.19522. View

4.
Israelian L, Nitschke S, Wang P, Zhao X, Perri A, Lee J . Ppp1r3d deficiency preferentially inhibits neuronal and cardiac Lafora body formation in a mouse model of the fatal epilepsy Lafora disease. J Neurochem. 2020; 157(6):1897-1910. PMC: 7936008. DOI: 10.1111/jnc.15176. View

5.
Ricci G, Volpi L, Pasquali L, Petrozzi L, Siciliano G . Astrocyte-neuron interactions in neurological disorders. J Biol Phys. 2009; 35(4):317-36. PMC: 2750745. DOI: 10.1007/s10867-009-9157-9. View